• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Waters Corporation

    3/17/26 5:27:04 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    FWP 1 d110429dfwp.htm FWP FWP

    Free Writing Prospectus

    Filed Pursuant to Rule 433

    Registration Statement Nos. 333-294314; 333-294314-01; 333-294314-02; 333-294314-03;

    333-294314-04; 333-294314-05; 333-294314-06; 333-294314-07; 333-294314-08;

    333-294314-09; 333-294314-10; 333-294314-11; and 333-294314-12

    PRICING TERM SHEET

    Augusta SpinCo Corporation (the “Company”)

    March 17, 2026

    $650,000,000 4.321% Senior Notes due 2027

     

    Issuer:    Augusta SpinCo Corporation
    Offering Format:    SEC Registered
    Ratings*:    Baa2 / BBB (Stable / Stable)
    Principal Amount:    $650,000,000
    Offering Price:    100.000% of principal amount
    Trade Date:    March 17, 2026
    Settlement Date**:    March 23, 2026 (T+4)
    Maturity Date:    September 23, 2027
    Coupon:    4.321%
    Benchmark Treasury:    3.375% due February 29, 2028
    Spread to Benchmark Treasury:    +65 basis points
    Benchmark Treasury Price and Yield:    99-141⁄4 / 3.671%
    Yield to Maturity:    4.321%
    Interest Payment Dates:    Semi-annually on March 23 and September 23, commencing on September 23, 2026
    Regular Record Dates:    March 8 and September 8
    Redemption Provisions:    The 2027 Notes will not be redeemable prior to their maturity
    Denominations:    $2,000 x $1,000
    CUSIP:    051473 AB2
    ISIN:    US051473AB24

    $600,000,000 4.398% Senior Notes due 2029

     

    Issuer:    Augusta SpinCo Corporation
    Offering Format:    SEC Registered
    Ratings*:    Baa2 / BBB (Stable / Stable)
    Principal Amount:    $600,000,000
    Offering Price:    100.000% of principal amount
    Trade Date:    March 17, 2026
    Settlement Date**:    March 23, 2026 (T+4)
    Maturity Date:    March 23, 2029
    Coupon:    4.398%
    Benchmark Treasury:    3.500% due March 15, 2029
    Spread to Benchmark Treasury:    +72 basis points
    Benchmark Treasury Price and Yield:    99-16 / 3.678%
    Yield to Maturity:    4.398%


    Interest Payment Dates:    Semi-annually on March 23 and September 23, commencing on September 23, 2026
    Regular Record Dates:    March 8 and September 8
    Redemption Provisions:   

    Par call:

       At any time on or after February 23, 2029 (one month prior to the maturity date), the Company may redeem the 2029 Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date

    Make-whole call:

       At any time and from time to time prior to February 23, 2029 (one month prior to the maturity date), the Company may, at its option, redeem the 2029 Notes, in whole or in part, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2029 Notes to be redeemed; and (2)(a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points less (b) interest accrued to the date of redemption, plus accrued and unpaid interest thereon to, but excluding, the redemption date
    Denominations:    $2,000 x $1,000
    CUSIP:    051473 AC0
    ISIN:    US051473AC07

    $750,000,000 4.656% Senior Notes due 2031

     

    Issuer:    Augusta SpinCo Corporation
    Offering Format:    SEC Registered
    Ratings*:    Baa2 / BBB (Stable / Stable)
    Principal Amount:    $750,000,000
    Offering Price:    100.000% of principal amount
    Trade Date:    March 17, 2026
    Settlement Date**:    March 23, 2026 (T+4)
    Maturity Date:    March 23, 2031
    Coupon:    4.656%
    Benchmark Treasury:    3.500% due February 28, 2031
    Spread to Benchmark Treasury:    +87 basis points
    Benchmark Treasury Price and Yield:    98-23 / 3.786%
    Yield to Maturity:    4.656%
    Interest Payment Dates:    Semi-annually on March 23 and September 23, commencing on September 23, 2026
    Regular Record Dates:    March 8 and September 8
    Redemption Provisions:   

    Par call:

       At any time on or after February 23, 2031 (one month prior to the maturity date), the Company may redeem the 2031 Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the 2031 Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date


    Make-whole call:

       At any time and from time to time prior to February 23, 2031 (one month prior to the maturity date), the Company may, at its option, redeem the 2031 Notes, in whole or in part, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2031 Notes to be redeemed; and (2)(a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points less (b) interest accrued to the date of redemption, plus accrued and unpaid interest thereon to, but excluding, the redemption date
    Denominations:    $2,000 x $1,000
    CUSIP:    051473 AD8
    ISIN:    US051473AD89

    $750,000,000 4.945% Senior Notes due 2033

     

    Issuer:    Augusta SpinCo Corporation
    Offering Format:    SEC Registered
    Ratings*:    Baa2 / BBB (Stable / Stable)
    Principal Amount:    $750,000,000
    Offering Price:    100.000% of principal amount
    Trade Date:    March 17, 2026
    Settlement Date**:    March 23, 2026 (T+4)
    Maturity Date:    March 23, 2033
    Coupon:    4.945%
    Benchmark Treasury:    3.750% due February 28, 2033
    Spread to Benchmark Treasury:    +97 basis points
    Benchmark Treasury Price and Yield:    98-20+ / 3.975%
    Yield to Maturity:    4.945%
    Interest Payment Dates:    Semi-annually on March 23 and September 23, commencing on September 23, 2026
    Regular Record Dates:    March 8 and September 8
    Redemption Provisions:   

    Par call:

       At any time on or after January 23, 2033 (two months prior to the maturity date), the Company may redeem the 2033 Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the 2033 Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date

    Make-whole call:

       At any time and from time to time prior to January 23, 2033 (two months prior to the maturity date), the Company may, at its option, redeem the 2033 Notes, in whole or in part, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2033 Notes to be redeemed; and (2)(a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 15 basis points less (b) interest accrued to the date of redemption, plus accrued and unpaid interest thereon to, but excluding, the redemption date


    Denominations:    $2,000 x $1,000
    CUSIP:    051473 AE6
    ISIN:   

    US051473AE62

    $750,000,000 5.245% Senior Notes due 2036

     

    Issuer:    Augusta SpinCo Corporation
    Offering Format:    SEC Registered
    Ratings*:    Baa2 / BBB (Stable / Stable)
    Principal Amount:    $750,000,000
    Offering Price:    100.000% of principal amount
    Trade Date:    March 17, 2026
    Settlement Date**:    March 23, 2026 (T+4)
    Maturity Date:    March 23, 2036
    Coupon:    5.245%
    Benchmark Treasury:    4.125% due February 15, 2036
    Spread to Benchmark Treasury:    +105 basis points
    Benchmark Treasury Price and Yield:    99-14/ 4.195%
    Yield to Maturity:    5.245%
    Interest Payment Dates:    Semi-annually on March 23 and September 23, commencing on September 23, 2026
    Regular Record Dates:    March 8 and September 8
    Redemption Provisions:   

    Par call:

       At any time on or after December 23, 2035 (three months prior to the maturity date), the Company may redeem the 2036 Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the 2036 Notes to be redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date

    Make-whole call:

       At any time and from time to time prior to December 23, 2035 (three months prior to the maturity date), the Company may, at its option, redeem the 2036 Notes, in whole or in part, at a redemption price equal to the greater of (1) 100% of the principal amount of the 2036 Notes to be redeemed; and (2)(a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 20 basis points less (b) interest accrued to the date of redemption, plus accrued and unpaid interest thereon to, but excluding, the redemption date
    Denominations:    $2,000 x $1,000
    CUSIP:   

    051473 AF3

    ISIN:   

    US051473AF38

    * * * * *


    Joint Book-Running Managers:   

    Barclays Capital Inc.

    Citigroup Global Markets Inc.

    J.P. Morgan Securities LLC

    BofA Securities, Inc.

    HSBC Securities (USA) Inc.

    Citizens JMP Securities, LLC

    PNC Capital Markets LLC

    Truist Securities, Inc.

    Co-Managers:   

    DNB Carnegie, Inc.

    Guggenheim Securities, LLC

    KeyBanc Capital Markets Inc.

    TD Securities (USA) LLC

    U.S. Bancorp Investments, Inc.

     

    *

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

    **

    Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, purchases or sales of securities in the secondary market generally are required to settle in one business day (T+1), unless the parties to any such transactions expressly agree otherwise. Accordingly, purchasers of the notes who wish to trade the notes prior to the business day preceding their date of delivery will be required, because the notes initially will settle in T+4, to specify an alternative settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes before the first business day prior to such settlement date should consult their own advisor.

     

     

    This pricing term sheet is not an offer to sell the securities and it is not a solicitation of an offer to buy the securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.

    The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, you may obtain a copy of the prospectus by calling Barclays Capital Inc. at 1-888-603-5847, Citigroup Global Markets Inc. at 1-800-831-9146, J.P. Morgan Securities LLC at 1-212-834-6081, BofA Securities, Inc. at 1-800-294-1322, HSBC Securities (USA) Inc. at 1-866-811-8049.

    Any disclaimers or notices that may appear on this pricing term sheet below the text of this legend are not applicable to this pricing term sheet and should be disregarded. Such disclaimers may have been electronically generated as a result of this pricing term sheet having been sent via, or posted on, Bloomberg or another electronic mail system.

    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    6/2/2026$425.00Outperform
    Wolfe Research
    4/6/2026$350.00In-line → Outperform
    Evercore ISI
    2/10/2026$360.00In-line
    Evercore ISI
    2/10/2026$425.00Buy
    Citigroup
    2/10/2026$400.00Overweight
    Barclays
    1/6/2026$440.00Buy
    Guggenheim
    1/5/2026Outperform
    William Blair
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/14/26 4:55:54 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Bennett Jianqing

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    4/7/26 4:36:35 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Jiang Wei

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    4/2/26 5:03:05 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fearon Richard H bought $306,340 worth of shares (1,000 units at $306.34), increasing direct ownership by 43% to 3,302 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    3/10/26 4:21:34 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

    FDA 510(k)-cleared BD BACTEC™ FXI Culture System now available to U.S. market, enabling broader access to confident bloodstream infection diagnostics.Achieves a 3-hour faster time to detection (~15% reduction) versus the prior-generation system, per clinical study data, enabling earlier targeted sepsis prevention.Fully automated solution delivers an industry-leading 50% increase in vial loading and up to 960-vial per module capacity, maximizing walk-away time.MILFORD, Mass., June 3, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in

    6/3/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

    Delivers up to 20x improvement in MS/MS sensitivity and 2x faster acquisition speeds, enabling deeper biological insight for next-generation multiomics, therapeutic, and high-throughput workflows.Identifies up to 40% more lipids by LC‑MS/MS than the leading alternative benchtop high‑resolution mass spectrometer, advancing lipidomics research and disease understanding.Sets a new benchmark for throughput in high-resolution spatial analysis with the DESI XS source, supporting higher-confidence studies of disease and treatment response.MILFORD, Mass., June 1, 2026 /CNW/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics—Waters Corporation (NYSE:WAT) today introduced the Waters Xevo™

    6/1/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics

    >10x step-change in MS/MS sensitivity paired with multipass Cyclic™ Ion Mobility Spectrometry (IMS) reveals subtle biological differences for earlier, previously unattainable detection of disease signals.50% extended upper mass range and comprehensive suite of structural tools advance the development of next-generation biotherapeutics.Integrated MALDI XS and DESI XS imaging with high-resolution ion mobility enables direct visualization of molecules in tissue, improving understanding of how disease develops at the cellular level.MILFORD, Mass., June 1, 2026 /PRNewswire/ -- 74th ASMS Conference on Mass Spectrometry and Allied Topics— Waters Corporation (NYSE:WAT) today announced the launch of

    6/1/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    SEC Form SD filed by Waters Corporation

    SD - WATERS CORP /DE/ (0001000697) (Filer)

    5/29/26 4:15:28 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 8-K filed by Waters Corporation

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    5/22/26 4:15:20 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Waters Corporation

    10-Q - WATERS CORP /DE/ (0001000697) (Filer)

    5/12/26 4:16:20 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on Waters with a new price target

    Wolfe Research resumed coverage of Waters with a rating of Outperform and set a new price target of $425.00

    6/2/26 8:40:09 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Waters from In-line to Outperform and set a new price target of $350.00

    4/6/26 8:29:42 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results

    First Quarter 2026 HighlightsTotal reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses.Organic revenue grew 13% as reported and 11% in constant currency, exceeding the high end of the constant currency growth guidance range by 200 basis points – led by high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division.The Biosciences and Diagnostic Solutions businesses generated $520 million of reported revenue since the closing of the acquisition – $40 million above guidance – driven by traction from commercial execution and o

    5/5/26 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules First Quarter 2026 Earnings Conference Call

    MILFORD, Mass., April 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2026 financial results conference call on Tuesday, May 5, 2026 at 8:30 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 2, 2026, at midnight Eastern Time. About Waters CorporationWaters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innova

    4/20/26 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials